Gilead
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. Covers Gilead Sciences as a whole, including Kite, so Kite releases and job postings count with Gilead's.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 2 | claimed | claimed | 0 | 2 |
| Research labs and data | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 3 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Gilead scores 2 out of 10 for priority in AI in drug discovery, and delivery is shown as claimed: the company says AI is in use, but the sources show no identifiable system in operation. Its evidence is a stated aim to adopt and scale AI, research data science teams brought together, and a new Research Center at headquarters that opened in September 2026 with added research data science capacity. For research labs and data, no eligible company disclosure was identified. No AI discovery commitment was made public in the last 12 months; the year before brought the Terray Therapeutics collaboration on its tNova platform and the announcement of the Research Center as digitally enabled labs. On 6 October 2026 Gilead had 2 AI in drug discovery roles open, including an AI/ML scientist for biologics design, and 3 research labs and data roles, including a research systems software engineer and a protein therapeutics automation engineer.
AI in drug discovery
What the company says: Priority 2
Gilead will build and maintain leadership capabilities to govern AI responsibly while applying these powerful new tools to support drug discovery, improve the employee experience and expedite responsible business reporting efforts.
2025 Responsible Business and Impact Report, 21 Apr 2026, p. 10
Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration
Adopt and Scale AI to Transform How We Work
Gilead recognizes the growing strategic importance of AI to the company's mission to discover, develop and deliver innovative therapeutics
Across Gilead, AI is enabling new levels of agility and insight that will continue to shape how we work in 2026 and beyond.
What it shows running: Delivery claimed, claimed
today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science
By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 1
- Terray Therapeutics AI discovery collaboration (tNova platform): Multi-target small-molecule discovery collaboration; Terray applies its generative AI tNova platform to Gilead-selected targets; Gilead holds licence option. New, announced, 17 Dec 2024. Published by: joint release.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Senior Scientist, AI/ML (Biologics Design), United States - California - Foster City
- AI Data Science Lead - Research (Gilead & Kite), United States - North Carolina - Raleigh
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 1
- Foster City Research Center (digitally enabled research labs): New Foster City research building under construction, described as digitally enabled labs with autonomous robots, augmented reality and digital twins. New, in build, 29 Aug 2025. Published by: company.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 3
- Scientist, In Vivo High Throughput Screening & Analytics, United States - Pennsylvania - Philadelphia
- Staff Software Engineer, Research Systems, United States - California - Foster City
- Automation Engineer, Protein Therapeutics, United States - California - Foster City
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- Who decides on lab automation, scheduling software and LIMS or ELN choices: Research Informatics, departmental automation teams such as Protein Therapeutics, or Kite Research, and does any of the $2 billion Gilead has stated for digital and advanced engineering fund this work?
- Who decides whether Gilead licenses an external AI discovery platform, as with Terray, or builds in Research Data Sciences, when research AI roles also sit in the IT Data and AI organisation, and which route do such deals take: Research, business development or IT procurement?
Coverage limits
The investor site returned a Cloudflare challenge, so results slides, webcasts and transcripts were not read, and no 10-K was read for either year. Business Wire, GlobeNewswire, Fierce Biotech, Fierce Pharma and several trade sites blocked access, and the newswire index reached back only to October 2025, so the year before the last 12 months is covered more thinly. A capped search budget left some searches unrun, including checks for Terray and Genesis milestones and for Kite AI collaborations. The lack of a research labs and data disclosure is a search result, not proof that no such work exists.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call